Bausch + Lomb to Share New Data on Dry Eye Management, Contact Lens Performance and Perioperative Outcomes at SECO 2026

  • New phase 4 data for MIEBO® show meaningful improvements in signs and symptoms of dry eye disease in cataract surgery patients without compromising preoperative measurement accuracy
  • Real world provider reported outcomes for XIIDRA® reinforce its rapid and sustained symptom relief for patients with dry eye disease
  • Bausch + Lomb INFUSE® for Astigmatism data demonstrate strong visual clarity, comfort and handling among new toric contact lens wearers
  • Educational events to offer evidence based guidance and best practices on several products from across Bausch + Lomb's Vision Care, Consumer and Pharmaceuticals portfolios

VAUGHAN, Ontario, Feb. 23, 2026 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced three scientific poster presentations at SECO International Annual Conference in Atlanta, Feb. 25 to March 1, 2026. The company will also host several educational events.

The new data will feature MIEBO (perfluorohexyloctane ophthalmic solution), XIIDRA (lifitegrast ophthalmic solution) 5% and Bausch + Lomb INFUSE for Astigmatism contact lenses. A new phase 4 study of MIEBO demonstrates meaningful improvements in signs and symptoms of dry eye disease in cataract surgery patients while maintaining the accuracy of preoperative measurements. Additional real world, provider reported outcomes reinforce the rapid and sustained symptom relief associated with XIIDRA in the management of dry eye disease. Data evaluating Bausch + Lomb INFUSE for Astigmatism also showed strong visual clarity, comfort and ease of handling among new toric lens wearers.

Several sponsored educational events will focus on evidence based dry eye management, as well as clinical insights and best practices related to products in the company's Vision Care, Consumer and Pharmaceuticals portfolios. These products include MIEBO, XIIDRA, VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024%, Blink® eye drops, LUMIFY® redness reliever eye drops, Bausch + Lomb INFUSE and PreserVision® AREDS 2 and the new PreserVision AREDS3 formula eye vitamins.

See below for the complete list of Bausch + Lomb events and scientific presentations.

Poster Presentations

  • "New Contact Lens Wearers' Real-World Experience with a Novel Daily Disposable Toric Contact Lens." Womack.
  • "Perioperative Use of Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery." Schweitzer.
  • "Real-World Experience with Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease: A Provider Survey." Brujic et al.

Educational Events
Wednesday, Feb. 25
A Family of Eyecare Products with Innovations for Every Stage of Life

  • 11:00-11:55 p.m. ET; Georgia World Congress Center, 285 Andrew Young International Blvd. NW, Room: 411/412
  • Speakers: Mile Brujic, OD, FAAO; Shane Kannar, OD; Cecelia Koetting, OD, FAAO

AREDS3: An Evolved PreserVision® Formula

  • 5:30-6:30 p.m. ET; Georgia World Congress Center, 285 Andrew Young International Blvd. NW, Room: 411/412
  • Speaker: Jeffry Gerson, OD, FAAO

Thursday, Feb. 26
Know Your Dry Eye: Navigating the Challenges of Real-World Dry Eye Cases

  • Registration begins at 6:45 p.m. ET, program starts at 7:00 p.m. ET; Ruth's Chris (Embassy Suites Hotel, 267 Marietta Street NW)
  • Speakers: Mitch Ibach OD, FAAO; Nate Lighthizer OD, FAAO
  • Registration link

Friday, Feb. 27
Practice Dry Eye Pathways: From Evidence to Implementation

  • 8:00-9:00 a.m. ET; Thomas M. Menino Convention Center, 415 Summer Street, Meeting Level 2, Room 203
  • Speaker: Jade Coats, OD; Paul Karpecki, OD

OTC Eye Drops: More than Meets the Eye, Featuring NEW Blink and LUMIFY Products

  • 1:00-2:00 p.m. ET; Georgia World Congress Center, 285 Andrew Young International Blvd. NW, Room: 411/412
  • Speaker: Cecelia Koetting, OD, FAAO, Dipl-ABO

Saturday, Feb. 28
VYZULTA: A Branded First-Line Treatment from the Start

  • 8:00-8:25 a.m. ET; Georgia World Congress Center, 285 Andrew Young International Blvd. NW, Room: 411/412
  • Speakers: Jessica Steen, OD, FAAO; Walt Whitley, MBA, OD, FAAO

###

Important Safety Information for MIEBO

INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Click here for full Prescribing Information for MIEBO.

Important Safety Information for XIIDRA

Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for full Prescribing Information for Xiidra.

Important Safety Information for VYZULTA

INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here to see full Prescribing Information for Vyzulta.

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we're turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

Media Contacts:

Kristy Marks
[email protected]
(908) 927-0683

Caryn Marshall
[email protected]
(908) 493-1381

©2026 Bausch + Lomb.
MTB.0077.USA.26

Back to Press Releases